Lactobacillus rhamnosus HN001

Active Ingredient: L. rhamnosus HN001

The information shared here should not be regarded as claims or health benefits related to the products sold on this website. 

What is Lactobacillus rhamnosus HN001?

According to the source (Power of Probiotics

"Lactobacillus rhamnosus HN001 (l. rhamnosus HN001) had a GRAS (generally recognized as safe) application filed to the US FDA by Fonterra for its use in infant formula in 2009. The strain, which was isolated from a cheddar cheese that has been consumed in New Zealand for more than 20 years, is known commercially as L. rhamnosus DR20 or simply DR20 from the New Zealand Dairy Board and as HOWARU Rhamnosus from Danisco."


"Lactobacillus rhamnosus HN001=L. rhamnosus HN001=Lactobacillus rhamnosus DR20=L. rhamnosus DR20=DR20=HOWARU Rhamnosus"

Studies on:


Study Title: Early supplementation with Lactobacillus rhamnosus HN001 reduces eczema prevalence to 6 years: does it also reduce atopic sensitization?

Source: Wiley Online Library

Authors: K. Wickens T. V. Stanley E. A. Mitchell C. Barthow P. Fitzharris G. Purdie R. Siebers P. N. Black J. Crane
First published: 05 June 2013

 According to the authors of the study: "Using a double‐blind randomized placebo‐controlled trial (Australian New Zealand Clinical Trials Registry: ACTRN12607000518460), we have shown that in a high‐risk birth cohort, maternal supplementation from 35 weeks gestation until 6 months if breastfeeding and infant supplementation from birth until 2 years with Lactobacillus rhamnosus HN001 (HN001) (6 × 109 cfu/day) halved the cumulative prevalence of eczema at 2 and 4 years." 

Depression, Anxiety

A research paper looked at "Effect of Lactobacillus rhamnosus HN001 in Pregnancy on Postpartum Symptoms of Depression and Anxiety: A Randomised Double-blind Placebo-controlled Trial"  

Authors: R.F.SlykermanaF.HoodbK.WickensbJ.M.D.ThompsonaC.BarthowbR.MurphycJ.KangbJ.RowdenaP.StonedJ.CranebT.StanleyeP.AbelsbG.Purdief R.MaudegE.A.Mitchellathe Probiotic in Pregnancy Study Group

Highlights (source: EbioMedicine) as mentioned by the Authors:

The microbiome-gut-brain axis may be important for mental health.

The authors conducted a study of probiotic supplementation in pregnancy and 6 months after delivery if breastfeeding.

The probiotic treatment group reported significantly lower depression and anxiety scores than those in the placebo group.

According to the authors, "there is mounting evidence from animal studies that the microbiome-gut-brain axis may be important for mental health. Depression and anxiety in pregnancy and after birth affect 10–15% of women, although many are not recognized or treated. We conducted a double-blind placebo-controlled study of probiotic (Lactobacillus rhamnosus HN001) supplementation (from early pregnancy through to 6 months after delivery if breastfeeding) on postnatal symptoms of depression and anxiety in a group (n = 380) of healthy women. Mothers in the probiotic treatment group reported significantly lower depression and anxiety scores than those in the placebo group."

Immunity Enhancing Effects

Research paper: Systemic Immunity-Enhancing Effects in Healthy Subjects Following Dietary Consumption of the Lactic Acid Bacterium Lactobacillus rhamnosus HN001   

Source: Taylor Francis Online

Authors: Ying-H. Sheih , MD, Bor-L. Chiang , MD, Ling-H. Wang , MD, Chuh-K. Liao , MD & Harsharnjit S. Gill

The objective of the study was "to determine the effects of the probiotic lactic acid bacterium, Lactobacillus rhamnosus HN001, on natural cellular immunity when delivered orally in normal low-fat milk (LFM) or lactose-hydrolyzed low-fat milk (LFM-LH)."

The Conclusion as stated by the Authors: "Dietary consumption of L. rhamnosus HN001, in a base of low-fat milk or lactose-hydrolyzed low-fat milk, appears to enhance systemic cellular immune responses and may be useful as a dietary supplement to boost natural immunity."


Study: Safety assessment of potential probiotic lactic acid bacterial strains Lactobacillus rhamnosus HN001, Lb. acidophilus HN017, and Bifidobacterium lactis HN019 in BALB/c mice

Source: ScienceDirect

Authors: J.SZhouaQShuaK.JRutherfurdaJPrasadaM.JBirtlesbP.KGopalcH.SGilla

The general safety of immune-enhancing lactic acid bacteria (LAB) strains Lactobacillus rhamnosus HN001 (DR20™), Lb. acidophilus HN017, and Bifidobacterium lactis HN019 (DR10™) was investigated in a feeding trial involving animals.

The Conclusion as stated by the Authors:  "The results obtained in this study suggest that the potentially probiotic LAB strains HN001, HN017, and HN019 are non-toxic for mice and are therefore likely to be safe for human use."